Cumulative Tenofovir Exposure Among Patients With Human Immunodeficiency Virus/Hepatitis B Coinfection With Differential Viral Suppression-Reference-Cited by-同舟云学术

Cumulative Tenofovir Exposure Among Patients With Human Immunodeficiency Virus/Hepatitis B Coinfection With Differential Viral Suppression

Published:2024-05-03 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Zhang Helen L¹^ORCID,Mock Meredith²,Bushman Lane³,Anderson Peter L³,Kiser Jennifer J³,Naggie Susanna⁴

Affiliation:

1. Hospital Medicine Section, Medicine Specialty Service, Durham VA Medical Center , Durham, North Carolina , USA

2. Department of Physician Assistant Studies, The George Washington University School of Medicine and Health Sciences , Washington D.C. , USA

3. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus , Aurora, Colorado , USA

4. Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina , USA

Abstract

Abstract This case-control study explored cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatis B virus (HIV/HBV) coinfection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n = 4) compared to those with complete suppression (n = 5) (516 vs 1456 fmol/punch).

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae241/58181001/ciae241.pdf

Reference15 articles.

1. Natural history of chronic hepatitis B in co-infected patients;Puoti;J Hepatol,2006

2. Hepatitis B and human immunodeficiency virus coinfection;Thio;Hepatology,2009

3. Hepatitis B virus (HBV) replication during tenofovir therapy is frequent in human immunodeficiency virus/HBV coinfection;Hofmann;Clin Infect Dis,2023

4. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus;Matthews;Clin Infect Dis,2013

5. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy;Hafkin;J Viral Hepat,2014